Using a new formulation of Nerofe, treating a patient with Stage 4 squamous cell lung cancer (positive for ST2), caused the complete disappearance of some tumors and a decrease in the size of other tumors. Increase in hepatic function.
New Nerofe Formulation for treatment of Stage 4 squamous cell lung cancer
29/11/2022Related Posts
-
Dr. Devary: Transforming “Cold Tumors” into “Hot Tumors”: Nerofe and DOX Synergy against KRAS Mutations
26/10/2023 -
Second FDA approved clinical trial in patients with pancreatic cancer and metastatic colorectal
18/12/2022ISK is excited to report the official opening of its second FDA approved clinical trial in the US in patients with pancreatic cancer and metastatic colorectal cancer at Georgetown University in Washington, D.C.
-
ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC
23/10/2022ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC
-
Georgetown University at Washington DC has signed a contract with ISK to run a clinical trial with patients with mtKRAS tumors
17/02/2022The prestigious medical center Georgetown University at Washington DC has sign a contract with ISK to run a clinical trial with patients with mtKRAS pancreas and colon cancers.
-
PHASE 1B/2A Clinical trial started
13/04/2021
